FDA Leadership Turmoil Sparks Uncertainty in Gene Therapy Sector
TL;DR Summary
The FDA's chief regulator of cell and gene therapies was ousted following a disagreement over the review process for a Duchenne muscular dystrophy therapy and ongoing management tensions, highlighting internal conflicts within the agency.
Topics:business#cell-therapy#duchenne-muscular-dystrophy#fda#health#management-style#regulatory-dispute
- Disagreements over Duchenne therapy, management style may have led to ouster of key FDA official STAT
- Gene Therapy Stocks Fall Amid More Turmoil at FDA Barron's
- Nicole Verdun Exits FDA as CBER Director Vinay Prasad ‘Consolidates Power’ BioSpace
- Industry disappointed as FDA puts gene therapy chief on leave Fierce Biotech
- Gene therapy faces fresh uncertainty as two more top FDA officials depart BioPharma Dive
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
85%
221 → 34 words
Want the full story? Read the original article
Read on STAT